Early studies suggested that pharmacological inhibition of PADI4 via pan-PAD inhibition with CL- and BB-CL- Amidine mildly improved clinical manifestations of SLE in murine models [20, 21]. This evidence concerns the gene PADI4 and systemic lupus erythematosus.